ChinaMart

China Biotech Week in Review: Earnings, Deals and Drug Development

LTUS (Lotus Pharmaceuticals) reaffirmed 2008 guidance on Friday. That guidance of $13.8M USD in net income is about .29/share fully diluted...making the PE for LTUS well under 4.
As far as I can tell, this makes LTUS the best value in the China Biopharma sector today.

American Oriental Bioengineering Considering Several Acquisition Targets

I was surprised to see AOB drop 10% on it's annual report and conference call yesterday. As an AOB shareholder for just over 3 years now, I still see a bright future for the company with organic growth of 30% and plenty of cash for acquisitions.
I also believe LTUS (Lotus Pharmaceuticals) is worth a look here, as the company has plans for a nasdaq listing, and is currently trading at a PE of 3 based on 2008 make good target of .28/share, with over 60% income growth yoy.